06/17/22 8:00 AMNasdaq : VYNE clinical trialVYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic DermatitisVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment ofRHEA-AIneutral
05/18/22 8:00 AMNasdaq : VYNE conferencesVYNE Therapeutics to Present at HC Wainwright & Co. Global Investment ConferenceVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that DavidRHEA-AIneutral
05/12/22 4:05 PMNasdaq : VYNE earningsVYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateAnnounced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBET TM BET inhibitor platform on May 17 th BRIDGEWATER, N.J., May 12, 2022RHEA-AIneutral
05/10/22 8:00 AMNasdaq : VYNE VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor PlatformVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment ofRHEA-AIneutral
05/06/22 8:00 AMNasdaq : VYNE conferencesVYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10thVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that DavidRHEA-AIneutral
04/07/22 8:00 AMNasdaq : VYNE clinical trialVYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic DermatitisVYNE Therapeutics Inc. (Nasdaq:RHEA-AIneutral
03/30/22 8:00 AMNasdaq : VYNE clinical trialVYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid ArthritisVYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibiting inflammation inRHEA-AIneutral
03/17/22 8:00 AMNasdaq : VYNE earningsVYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate UpdateVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or theRHEA-AIneutral
03/07/22 7:00 AMNasdaq : VYNE clinical trialVYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of VitiligoVYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin disorder. VYN201 0.1% and 1% demonstrated upregulaton of the WNT signalling pathway, recognized asRHEA-AIneutral
03/03/22 8:00 AMNasdaq : VYNE conferencesVYNE Therapeutics to Present at 42nd Annual Cowen Healthcare ConferenceVYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that DavidRHEA-AIneutral